Form 4: Exact Sciences EVP Sells Shares Post-Abbott Merger

Exact Sciences' EVP of Human Resources, Sarah Condella, reported the disposition of all her common stock, options, and restricted stock units following the company's acquisition by Abbott Laboratories.

Summary

• Exact Sciences Corporation was acquired by Abbott Laboratories through a merger, with the effective date being March 23, 2026.
• Exact Sciences became a direct, wholly-owned subsidiary of Abbott Laboratories.
• The merger consideration for each share of Exact Sciences common stock was $105.00 in cash.
• Sarah Condella, EVP of Human Resources, reported the disposition of 191,891 shares of common stock and 6,368 shares held in a 401(k) plan, all converted into the merger consideration.
• Performance-based restricted stock units (PSUs) were deemed fully vested based on actual achievement levels as of November 19, 2025, and converted into the $105.00 cash merger consideration.
• Stock options with exercise prices below $105.00 were cancelled and converted into cash payments based on the difference between the merger consideration and the exercise price.
• A total of 48,019 stock options (21,948, 11,700, 7,790, 6,581) were disposed of.
• Restricted stock units (RSUs) granted on or after November 19, 2025, were assumed by Abbott Laboratories as Parent restricted stock units on substantially the same terms.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as positive for shareholders who received the merger consideration, as it confirms the successful completion of a significant corporate transaction and provides a clear cash exit. The score reflects the orderly execution of a pre-announced event.

Positives

• The merger consideration of $105.00 per share provides a clear cash value for shareholders.
• Performance-based restricted stock units were fully vested, ensuring payout for performance achievements.
• In-the-money stock options were converted to cash, allowing option holders to realize value.

Negatives

• Exact Sciences Corporation ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary.
• Shareholders no longer participate in the future growth of Exact Sciences as a standalone company.

Future Outlook

Exact Sciences Corporation will operate as a direct, wholly-owned subsidiary of Abbott Laboratories. Certain restricted stock units granted on or after November 19, 2025, will be assumed by Abbott Laboratories and will vest in four equal annual installments starting February 25, 2027.

Industry Context

StockSavvy.ai notes that this acquisition by Abbott Laboratories of Exact Sciences Corporation signifies a strategic move by Abbott to potentially expand its diagnostics or medical device portfolio, integrating Exact Sciences' capabilities. Such mergers are common in the healthcare and biotechnology sectors as larger players seek to consolidate market share, acquire innovative technologies, or achieve synergistic benefits. The cash consideration of $105.00 per share reflects a valuation agreed upon by both parties, likely after extensive due diligence and market analysis.

Comparison to Industry Standards

• StockSavvy.ai observes that the cash-out merger structure is a standard approach for acquisitions, providing immediate liquidity to target company shareholders.
• The valuation of $105.00 per share would typically be assessed against comparable transactions in the diagnostics or life sciences sector, considering factors like revenue multiples, EBITDA multiples, and strategic premiums.
• For instance, recent acquisitions in the diagnostics space, such as Roche's acquisition of Spark Therapeutics or Danaher's acquisition of General Electric's biopharma business, involved significant premiums over pre-announcement stock prices, reflecting the strategic value of the acquired assets.
• Without specific financial details of Exact Sciences at the time of the merger agreement (November 19, 2025), a direct comparison of the premium paid is not possible from this filing alone, but the structure aligns with industry norms for such transactions.

Stakeholder Impact

• Shareholders: Received $105.00 cash per share, ceasing to be shareholders of Exact Sciences.
• Employees (specifically Sarah Condella): Her equity holdings were converted to cash or assumed by the acquiring company, indicating a change in the structure of her compensation and ownership.
• Exact Sciences as an entity: Became a wholly-owned subsidiary of Abbott Laboratories.

Next Steps

• Exact Sciences will continue to operate as a wholly-owned subsidiary of Abbott Laboratories.
• Certain assumed Restricted Stock Units will begin vesting on February 25, 2027.

Key Dates

Keywords

Exact Sciences, EXAS, Abbott Laboratories, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, PSU, Corporate Governance, Beneficial Ownership